Tenaya Therapeutics, Inc. financial data

Symbol
TNYA on Nasdaq
Location
South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 534 % -7.28%
Debt-to-equity 24.3 % +15.1%
Return On Equity -95.5 % -10.8%
Return On Assets -76.8 % -7.94%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 167M shares +110%
Common Stock, Shares, Outstanding 86.5M shares +26.7%
Entity Public Float 171M USD -37.2%
Common Stock, Value, Issued 16K USD +100%
Weighted Average Number of Shares Outstanding, Basic 163M shares +89.6%
Weighted Average Number of Shares Outstanding, Diluted 163M shares +89.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 72.5M USD -20.3%
General and Administrative Expense 24.7M USD -22.3%
Operating Income (Loss) -97.2M USD +20.8%
Nonoperating Income (Expense) 2.95M USD -46.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -94.3M USD +19.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -94.3M USD +19.6%
Earnings Per Share, Basic 0 USD/shares +46.9%
Earnings Per Share, Diluted 0 USD/shares +46.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.3M USD +584%
Cash, Cash Equivalents, and Short-term Investments 56.3M USD -29.2%
Other Assets, Current 990K USD -29.4%
Assets, Current 61.2M USD -28.2%
Property, Plant and Equipment, Net 29.4M USD -22%
Operating Lease, Right-of-Use Asset 10.1M USD -20.3%
Other Assets, Noncurrent 4.24M USD -12.9%
Assets 105M USD -25.3%
Accounts Payable, Current 2.84M USD -51.3%
Accrued Liabilities, Current 7.44M USD +1.56%
Liabilities, Current 13.2M USD -18.3%
Operating Lease, Liability, Noncurrent 8.6M USD -25.4%
Other Liabilities, Noncurrent 301K USD +9.06%
Liabilities 22.1M USD -21%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1K USD +98.5%
Retained Earnings (Accumulated Deficit) -585M USD -19.2%
Stockholders' Equity Attributable to Parent 82.9M USD -26.4%
Liabilities and Equity 105M USD -25.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.1M USD +19.4%
Net Cash Provided by (Used in) Financing Activities 50.3M USD +7.46%
Net Cash Provided by (Used in) Investing Activities 22.3M USD
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 86.5M shares +26.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 49.4M USD +263%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 56.7M USD +556%
Deferred Tax Assets, Valuation Allowance 126M USD +24.7%
Deferred Tax Assets, Gross 130M USD +24.3%
Operating Lease, Liability 11.5M USD -20.7%
Payments to Acquire Property, Plant, and Equipment 383K USD -32.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -94.3M USD +19.3%
Lessee, Operating Lease, Liability, to be Paid 14.1M USD -22.8%
Property, Plant and Equipment, Gross 68.3M USD -0.17%
Operating Lease, Liability, Current 2.93M USD -2.82%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.78M USD -2.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.86M USD +0.08%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.54M USD -31%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.47M USD -61%
Deferred Tax Assets, Operating Loss Carryforwards 66.6M USD +26.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 6.36M USD +40.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.52M USD +2.99%
Operating Lease, Payments 989K USD -25.8%
Additional Paid in Capital 668M USD +10.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.66M USD +23.5%
Deferred Tax Assets, Net of Valuation Allowance 3.39M USD +11.7%
Share-based Payment Arrangement, Expense 14.1M USD -15.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%